[go: up one dir, main page]

DK1618195T3 - Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA) - Google Patents

Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)

Info

Publication number
DK1618195T3
DK1618195T3 DK04730318T DK04730318T DK1618195T3 DK 1618195 T3 DK1618195 T3 DK 1618195T3 DK 04730318 T DK04730318 T DK 04730318T DK 04730318 T DK04730318 T DK 04730318T DK 1618195 T3 DK1618195 T3 DK 1618195T3
Authority
DK
Denmark
Prior art keywords
myc
nucleic acids
peptide nucleic
pna
antigen peptide
Prior art date
Application number
DK04730318T
Other languages
Danish (da)
English (en)
Inventor
Roberto Tonelli
Raffaele Fronza
Andrea Pession
Stefano Sforza
Roberto Corradini
Rosangela Marchelli
Original Assignee
Univ Bologna Alma Mater
Univ Parma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater, Univ Parma filed Critical Univ Bologna Alma Mater
Application granted granted Critical
Publication of DK1618195T3 publication Critical patent/DK1618195T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181Peptide nucleic acid, PNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DK04730318T 2003-04-29 2004-04-29 Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA) DK1618195T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000860A ITMI20030860A1 (it) 2003-04-29 2003-04-29 Metodo per l'inibizione selettiva del gene n-myc
PCT/IB2004/001297 WO2004096826A2 (fr) 2003-04-29 2004-04-29 Procede pour l'inhibition selective du gene humain n-myc dans les tumeurs exprimant n-myc au moyen de proteines pna antisens et antigeniques

Publications (1)

Publication Number Publication Date
DK1618195T3 true DK1618195T3 (da) 2008-07-07

Family

ID=33398059

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04730318T DK1618195T3 (da) 2003-04-29 2004-04-29 Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)

Country Status (12)

Country Link
US (1) US7947657B2 (fr)
EP (1) EP1618195B1 (fr)
JP (1) JP4719670B2 (fr)
AT (1) ATE389017T1 (fr)
CA (1) CA2522890C (fr)
DE (1) DE602004012404T2 (fr)
DK (1) DK1618195T3 (fr)
ES (1) ES2303636T3 (fr)
IT (1) ITMI20030860A1 (fr)
PL (1) PL1618195T3 (fr)
PT (1) PT1618195E (fr)
WO (1) WO2004096826A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06012076A (es) * 2004-04-20 2007-01-25 Nastech Pharm Co Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero.
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
JP5108530B2 (ja) * 2005-12-26 2012-12-26 独立行政法人理化学研究所 ARID3bを標的とした神経芽腫の治療剤
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
US11827884B2 (en) 2017-05-15 2023-11-28 University Of Florida Research Foundation, Incorporated Core master regulators of glioblastoma stem cells
KR20220017919A (ko) * 2019-06-06 2022-02-14 덴카 주식회사 펩티드 핵산을 기반으로 한 아쥬반트

Also Published As

Publication number Publication date
DE602004012404T2 (de) 2009-03-26
ITMI20030860A1 (it) 2004-10-30
PL1618195T3 (pl) 2008-09-30
JP2006525010A (ja) 2006-11-09
WO2004096826A3 (fr) 2005-05-26
US20070020632A1 (en) 2007-01-25
ES2303636T3 (es) 2008-08-16
JP4719670B2 (ja) 2011-07-06
ATE389017T1 (de) 2008-03-15
PT1618195E (pt) 2008-06-24
CA2522890A1 (fr) 2004-11-11
WO2004096826A2 (fr) 2004-11-11
DE602004012404D1 (de) 2008-04-24
CA2522890C (fr) 2013-07-02
EP1618195B1 (fr) 2008-03-12
US7947657B2 (en) 2011-05-24
EP1618195A2 (fr) 2006-01-25

Similar Documents

Publication Publication Date Title
EP1750771A4 (fr) Micro-arn d'ilot pancreatique et methodes permettant d'inhiber ce dernier
CY1106991T1 (el) Αντιπολλαπλασιαστικη δραση ολιγονουκλεοτιδιων πλουσιων σε g και μεθοδος χρησιμοποιησης αυτων για την προσδεση σε νουκλεολινη
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
IN2015KN00290A (fr)
DE60335637D1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
EP1248794A4 (fr) Modulation antisens de l'expression de la proteine smad7
EP1513859A4 (fr) Suppresseur kinase de l'inactivation de ras pour traiter la tumorigenese induite par ras
WO2005086835A3 (fr) Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes
DK1618195T3 (da) Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)
EP1536006A4 (fr) Antigenes cancereux et leur utilisation
NO20055209D0 (no) Peptabody for cancerbehandling
DE50009365D1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
ATE534902T1 (de) Replikationsproteinn ciz1
EP1715896A4 (fr) Oligonucleotides antisens diriges contre la ribonucleotide reductase r2 et utilisation de ceux-ci dans des polytherapies destinees au traitement du cancer
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2003016343A3 (fr) UTILISATION DE αCP1, DE αCP2, ET DE HUR POUR MODULER L'EXPRESSION GENIQUE ET ACTIVER L'ANGIOGENESE
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
DE60128950D1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
ATE396262T1 (de) Rna polymerase i transkriptionsfaktor tif-ia
DE10393455D2 (de) DNA-Expressionskonstrukt zur multiplen Genexpression
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression
EP1702072A4 (fr) Therapie genique et modification genetique mettant en oeuvre des minichromosomes neocentromeriques